Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Targeting NF-kappaB in Waldenstrom macroglobulinemia.

Leleu X, Eeckhoute J, Jia X, Roccaro AM, Moreau AS, Farag M, Sacco A, Ngo HT, Runnels J, Melhem MR, Burwick N, Azab A, Azab F, Hunter Z, Hatjiharissi E, Carrasco DR, Treon SP, Witzig TE, Hideshima T, Brown M, Anderson KC, Ghobrial IM.

Blood. 2008 May 15;111(10):5068-77. doi: 10.1182/blood-2007-09-115170. Epub 2008 Mar 11.

2.

Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia.

Roccaro AM, Leleu X, Sacco A, Jia X, Melhem M, Moreau AS, Ngo HT, Runnels J, Azab A, Azab F, Burwick N, Farag M, Treon SP, Palladino MA, Hideshima T, Chauhan D, Anderson KC, Ghobrial IM.

Blood. 2008 May 1;111(9):4752-63. doi: 10.1182/blood-2007-11-120972. Epub 2008 Mar 3.

3.

Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia.

Roccaro AM, Sacco A, Jia X, Banwait R, Maiso P, Azab F, Flores L, Manier S, Azab AK, Ghobrial IM.

Clin Cancer Res. 2012 Dec 15;18(24):6609-22. doi: 10.1158/1078-0432.CCR-12-1532. Epub 2012 Oct 9.

4.

Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia.

Vilimas T, Mascarenhas J, Palomero T, Mandal M, Buonamici S, Meng F, Thompson B, Spaulding C, Macaroun S, Alegre ML, Kee BL, Ferrando A, Miele L, Aifantis I.

Nat Med. 2007 Jan;13(1):70-7. Epub 2006 Dec 17.

PMID:
17173050
5.

NF-kappaB as a therapeutic target in chronic lymphocytic leukemia.

Lopez-Guerra M, Colomer D.

Expert Opin Ther Targets. 2010 Mar;14(3):275-88. doi: 10.1517/14728221003598930. Review.

PMID:
20148715
6.

microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.

Roccaro AM, Sacco A, Chen C, Runnels J, Leleu X, Azab F, Azab AK, Jia X, Ngo HT, Melhem MR, Burwick N, Varticovski L, Novina CD, Rollins BJ, Anderson KC, Ghobrial IM.

Blood. 2009 Apr 30;113(18):4391-402. doi: 10.1182/blood-2008-09-178228. Epub 2008 Dec 12.

7.

9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways.

Guo C, Gasparian AV, Zhuang Z, Bosykh DA, Komar AA, Gudkov AV, Gurova KV.

Oncogene. 2009 Feb 26;28(8):1151-61. doi: 10.1038/onc.2008.460. Epub 2009 Jan 12.

PMID:
19137016
8.

Can NF-kappaB be a target for novel and efficient anti-cancer agents?

Olivier S, Robe P, Bours V.

Biochem Pharmacol. 2006 Oct 30;72(9):1054-68. Epub 2006 Sep 14. Review.

PMID:
16973133
10.

Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.

Salem K, Brown CO, Schibler J, Goel A.

Exp Hematol. 2013 Feb;41(2):209-18. doi: 10.1016/j.exphem.2012.10.002. Epub 2012 Oct 11.

11.

Targeting NF-kappaB in hematologic malignancies.

Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, Kroemer G.

Cell Death Differ. 2006 May;13(5):748-58. Review.

12.

The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis.

Böll B, Hansen H, Heuck F, Reiners K, Borchmann P, Rothe A, Engert A, Pogge von Strandmann E.

Blood. 2005 Sep 1;106(5):1839-42. Epub 2005 May 5.

13.
14.

Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, Baldwin AS Jr.

Cancer Res. 2001 May 1;61(9):3535-40.

15.

[Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].

Qu F, Xia B, Li X, Guo S, Zhang L, Tian C, Yu Y, Zhang Y.

Zhonghua Zhong Liu Za Zhi. 2015 Jun;37(6):412-7. Chinese.

PMID:
26463142
16.

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.

Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rötzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM, Sezer O.

Eur J Haematol. 2008 Feb;80(2):133-42. Epub 2007 Dec 20.

PMID:
18005386
17.

Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.

Sacco A, Aujay M, Morgan B, Azab AK, Maiso P, Liu Y, Zhang Y, Azab F, Ngo HT, Issa GC, Quang P, Roccaro AM, Ghobrial IM.

Clin Cancer Res. 2011 Apr 1;17(7):1753-64. doi: 10.1158/1078-0432.CCR-10-2130. Epub 2011 Feb 25.

18.

Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner.

Cardoso F, Durbecq V, Laes JF, Badran B, Lagneaux L, Bex F, Desmedt C, Willard-Gallo K, Ross JS, Burny A, Piccart M, Sotiriou C.

Mol Cancer Ther. 2006 Dec;5(12):3042-51. Epub 2006 Dec 5.

19.
20.

17-Acetoxyjolkinolide B irreversibly inhibits IkappaB kinase and induces apoptosis of tumor cells.

Yan SS, Li Y, Wang Y, Shen SS, Gu Y, Wang HB, Qin GW, Yu Q.

Mol Cancer Ther. 2008 Jun;7(6):1523-32. doi: 10.1158/1535-7163.MCT-08-0263.

Supplemental Content

Support Center